Citations (111)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Shaban Ahmad, Mussuvir Pasha KM, Khalid Raza, Misbahuddin M. Rafeeq, Alaa Hamed Habib, Murugesh Eswaran & Manoj Kumar Yadav. (2023) Reporting dinaciclib and theodrenaline as a multitargeted inhibitor against SARS-CoV-2: an in-silico study. Journal of Biomolecular Structure and Dynamics 41:9, pages 4013-4023.
Read now
Read now
Zhengchao Shen, Jian Wang, Kunbin Ke, Rong Chen, Aixue Zuo, Rongping Zhang, Weiping Wan, Xingxing Xie, Xuhua Li, Na Song, Hao Fu, Zhiwei Zhang, Enli Cai, Jihong Shen, Qingyu Zhang & Xinan Shi. (2021) Polyphyllin I, a lethal partner of Palbociclib, suppresses non-small cell lung cancer through activation of p21/CDK2/Rb pathway in vitro and in vivo. Cell Cycle 20:23, pages 2494-2506.
Read now
Read now
S.S. Liang, X.G. Liu, Y.X. Cui, S.L. Zhang, Q.G. Zhang & J.Z. Chen. (2021) Molecular mechanism concerning conformational changes of CDK2 mediated by binding of inhibitors using molecular dynamics simulations and principal component analysis. SAR and QSAR in Environmental Research 32:7, pages 573-594.
Read now
Read now
Lubaid Saleh, Caroline Wilson & Ingunn Holen. (2020) CDK4/6 inhibitors in breast cancer – from in vitro models to clinical trials. Acta Oncologica 59:2, pages 219-232.
Read now
Read now
Xin Wang, Kaiyuan Deng, Cheng Wang, Yao Li, Tianqi Wang, Zhi Huang, Yakun Ma, Peiqing Sun, Yi Shi, Shengyong Yang, Yan Fan & Rong Xiang. (2020) Novel CDKs inhibitors for the treatment of solid tumour by simultaneously regulating the cell cycle and transcription control. Journal of Enzyme Inhibition and Medicinal Chemistry 35:1, pages 414-423.
Read now
Read now
Eran Tallis & Gautam Borthakur. (2019) Novel treatments for relapsed/refractory acute myeloid leukemia with FLT3 mutations. Expert Review of Hematology 12:8, pages 621-640.
Read now
Read now
Joan Rou-En Choo & Soo-Chin Lee. (2018) CDK4-6 inhibitors in breast cancer: current status and future development. Expert Opinion on Drug Metabolism & Toxicology 14:11, pages 1123-1138.
Read now
Read now
Prithviraj Bose, Varsha Gandhi & Marina Konopleva. (2017) Pathways and mechanisms of venetoclax resistance. Leukemia & Lymphoma 58:9, pages 2026-2039.
Read now
Read now
P. Carrasco Salas, L. Fernández, M. Vela, D. Bueno, B. González, J. Valentín, P. Lapunzina & A. Pérez-Martínez. (2016) The role of CDKN2A/B deletions in pediatric acute lymphoblastic leukemia. Pediatric Hematology and Oncology 33:7-8, pages 415-422.
Read now
Read now
Jeffrey D Altenburg & Sherif S Farag. (2015) The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma. Expert Opinion on Investigational Drugs 24:2, pages 261-271.
Read now
Read now
Tomi K Sawyer, Joe C Wu, Jonathon R Sawyer & Jessie M English. (2013) Protein kinase inhibitors: breakthrough medicines and the next generation. Expert Opinion on Investigational Drugs 22:6, pages 675-678.
Read now
Read now
Articles from other publishers (100)
Harold A. Chinyama, Li Wei, Ntlotlang Mokgautsi, Bashir Lawal, Alexander T. H. Wu & Hsu-Shan Huang. (2023) Identification of CDK1, PBK, and CHEK1 as an Oncogenic Signature in Glioblastoma: A Bioinformatics Approach to Repurpose Dapagliflozin as a Therapeutic Agent. International Journal of Molecular Sciences 24:22, pages 16396.
Crossref
Crossref
Peddaguravagari Mounika, Bannimath Gurupadayya, Honnavalli Yogish Kumar & Bannimath Namitha. (2023) An Overview of CDK Enzyme Inhibitors in Cancer Therapy. Current Cancer Drug Targets 23:8, pages 603-619.
Crossref
Crossref
Ebtehal M Husseiny, Hamada S Abulkhair, Sanadelaslam SA El-Hddad, Nada Osama & Mona S El-Zoghbi. (2023) Aminopyridone-linked benzimidazoles: a fragment-based drug design for the development of CDK9 inhibitors. Future Medicinal Chemistry.
Crossref
Crossref
Wenjun Gui, Yumo Hang, Wang Cheng, Minqi Gao, Jiaquan Wu & Zhuqing Ouyang. (2023) Structural basis of CDK3 activation by cyclin E1 and inhibition by dinaciclib. Biochemical and Biophysical Research Communications 662, pages 126-134.
Crossref
Crossref
Mitra Zabihi, Ramin Lotfi, Amir-Mohammad Yousefi & Davood Bashash. (2022) Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities. Journal of Cancer Research and Clinical Oncology 149:4, pages 1585-1606.
Crossref
Crossref
Ashna Gupta, Gunjan Dagar, Ravi Chauhan, Hana Q. Sadida, Sara K. Almarzooqi, Sheema Hashem, Shahab Uddin, Muzafar A. Macha, Ammira S. Al-Shabeeb Akil, Tej K. Pandita, Ajaz A. Bhat & Mayank Singh. 2023. Control of Cell Cycle & Cell Proliferation. Control of Cell Cycle & Cell Proliferation
21
55
.
Nilmani, Maria D'costa, Anusha Bothe, Soumik Das, S. Udhaya Kumar, R. Gnanasambandan & C. George Priya Doss. 2023. Control of Cell Cycle & Cell Proliferation. Control of Cell Cycle & Cell Proliferation
125
177
.
Manzoor Ahmad Mir, Aabida Gul, Shazia Sofi & M. Sultan Khan. 2023. Therapeutic potential of Cell Cycle Kinases in Breast Cancer. Therapeutic potential of Cell Cycle Kinases in Breast Cancer
313
333
.
Xiao-Li He, Yong-Hong Hu, Jia-Mei Chen, Ding-Qi Zhang, Hai-Lin Yang, Lin-Zhang Zhang, Yong-Ping Mu, Hua Zhang, Gao-Feng Chen, Wei Liu & Ping Liu. (2022) SNS-032 attenuates liver fibrosis by anti-active hepatic stellate cells via inhibition of cyclin dependent kinase 9. Frontiers in Pharmacology 13.
Crossref
Crossref
Ping Guo, Shijia Zu, Shilong Han, Wendan Yu, Guoqing Xue, Xiaona Lu, Hua Lin, Xinrui Zhao, Haibo Lu, Chunyu Hua, Xinyu Wan, Liyuan Ru, Ziyue Guo, Hanxiao Ge, Kuan Lv, Guohui Zhang, Wuguo Deng, Cheng Luo & Wei Guo. (2022) BPTF inhibition antagonizes colorectal cancer progression by transcriptionally inactivating Cdc25A. Redox Biology 55, pages 102418.
Crossref
Crossref
Sisi Liu, Yaxin Li, Xilin Wei, Ran Zhang, Yifan Zhang & Chunyan Guo. (2022) Computational Investigations of Coumarin Derivatives as Cyclindependent
Kinase 9 Inhibitors Using 3D-QSAR, Molecular Docking and
Molecular Dynamics Simulation. Current Computer-Aided Drug Design 18:5, pages 363-380.
Crossref
Crossref
Xinren Wang, Xiaoyue Liu, Jianhang Huang, Chenhe Liu, Hongmei Li, Cong Wang, Qianqian Hong, Yan Lei, Jiawei Xia, Ziheng Yu, Ruinan Dong, Junyu Xu, Zhenlin Tu, ChunQi Duan, Shuwen Li, Tao Lu, Weifang Tang & Yadong Chen. (2022) Discovery of 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and selective CDK9 inhibitors that enable transient target engagement for the treatment of hematologic malignancies. European Journal of Medicinal Chemistry 238, pages 114461.
Crossref
Crossref
Theodora A. Constantin, Kyle K. Greenland, Anabel Varela-Carver & Charlotte L. Bevan. (2022) Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer. Oncogene 41:24, pages 3303-3315.
Crossref
Crossref
Jing-yue Yao, Shu Xu, Yue-ning Sun, Ye Xu, Qing-long Guo & Li-bin Wei. (2021) Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling. Acta Pharmacologica Sinica 43:4, pages 1033-1045.
Crossref
Crossref
Gareth P. Gregory, Shaji Kumar, Ding WangDaruka MahadevanPatricia WalkerNina Wagner-Johnston, Carolina EscobarRajat Bannerji, Divaya Bhutani, Julie ChangFrancisco J. Hernandez-IlizaliturriAndreas KleinJohn M. PagelWitold Rybka, Andrew J. Yee, Anne MohrbacherMo Huang, Mohammed Farooqui, Patricia Marinello & Hang Quach. (2022) Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. Blood Advances 6:4, pages 1232-1242.
Crossref
Crossref
Tobias Ettl, Daniela Schulz & Richard Bauer. (2022) The Renaissance of Cyclin Dependent Kinase Inhibitors. Cancers 14:2, pages 293.
Crossref
Crossref
Mayu Ono, Takaaki Oba, Tomohiro Shibata & Ken-ichi Ito. (2021) The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time. Journal of Cancer Research and Clinical Oncology 147:11, pages 3211-3224.
Crossref
Crossref
Bernard Barlaam, Chris De Savi, Allan Dishington, Lisa Drew, Andrew D. Ferguson, Douglas Ferguson, Chungang Gu, Sudhir Hande, Lorraine Hassall, Janet Hawkins, Alexander W. Hird, Jane Holmes, Michelle L. Lamb, Andrew S. Lister, Thomas M. McGuire, Jane E. Moore, Nichole O’Connell, Anil Patel, Kurt G. Pike, Ujjal Sarkar, Wenlin Shao, Darren Stead, Jeffrey G. Varnes, Melissa M. Vasbinder, Lei Wang, Liangwei Wu, Lin Xue, Bin Yang & Tieguang Yao. (2021) Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement. Journal of Medicinal Chemistry 64:20, pages 15189-15213.
Crossref
Crossref
Vildan Enisoğlu Atalay & Büşra Savaş. (2021) Development of potential inhibitors of cell division protein kinase 2 by ligand based drug design. Main Group Chemistry 20:3, pages 241-250.
Crossref
Crossref
Jianhang Huang, Xinren Wang, Ruinan Dong, Xiaoyue Liu, Hongmei Li, Tianyi Zhang, Junyu Xu, Chenhe Liu, Yanmin Zhang, Shaohua Hou, Weifang Tang, Tao Lu & Yadong Chen. (2021)
Discovery of
N
-(4-(3-isopropyl-2-methyl-2
H
-indazol-5-yl)pyrimidin-2-yl)-4-(4-methylpiperazin-1-yl)quinazolin-7-amine as a Novel, Potent, and Oral Cyclin-Dependent Kinase Inhibitor against Haematological Malignancies
. Journal of Medicinal Chemistry 64:17, pages 12548-12571.
Crossref
Crossref
Ni Made Pitri Susanti & Daryono Hadi Tjahjono. (2021) Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment. Molecules 26:15, pages 4462.
Crossref
Crossref
Rong Chen, Jennifer Tsai, Philip A. Thompson, Yuling Chen, Ping Xiong, Chaomei Liu, Francis Burrows, Mariela Sivina, Jan A. Burger, Michael J. Keating, William G. Wierda & William Plunkett. (2021) The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. Blood Cancer Journal 11:3.
Crossref
Crossref
Alessandra Ammazzalorso, Mariangela Agamennone, Barbara De Filippis & Marialuigia Fantacuzzi. (2021) Development of CDK4/6 Inhibitors: A Five Years Update. Molecules 26:5, pages 1488.
Crossref
Crossref
Fateme Moradi Moraddahande, Mona Shameli Houjghan, Amir-Mohammad Yousefi, Ava Safaroghli-Azar, Atieh Pourbagheri-Sigaroodi & Davood Bashash. (2021) Inhibitor of Multi-cyclin-dependent Kinases (AT7519) Reduced Survival of U937 Leukemic Cells and Enhanced Anti-leukemic Effect of Vincristine: A Highlight to CDK Inhibition Efficacy in Acute Leukemia. International Journal of Cancer Management 14:2.
Crossref
Crossref
Kai Yuan, Xiao Wang, Haojie Dong, Wenjian Min, Haiping Hao & Peng Yang. (2021) Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs. Acta Pharmaceutica Sinica B 11:1, pages 30-54.
Crossref
Crossref
Sepideh Izadi, Asma Moslehi, Hadiseh Kheiry, Fariba Karoon Kiani, Armin Ahmadi, Ali Masjedi, Sepideh Ghani, Behnam Rafiee, Vahid Karpisheh, Farnaz Hajizadeh, Fatemeh Atyabi, Akram Assali, Farnaz Sadat Mirzazadeh tekie, Afshin Namdar, Ghasem Ghalamfarsa, Mozhdeh Sojoodi & Farhad Jadidi-Niaragh. (2020) RETRACTED ARTICLE: Codelivery of HIF-1α siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression. Pharmaceutical Research 37:10.
Crossref
Crossref
Li Wang, Chen Hu, Aoli Wang, Cheng Chen, Jiaxin Wu, Zongru Jiang, Fengming Zou, Kailin Yu, Hong Wu, Juan Liu, Wenliang Wang, Zuowei Wang, Beilei Wang, Ziping Qi, Qingwang Liu, Wenchao Wang, Lili Li, Jian Ge, Jing Liu & Qingsong Liu. (2019) Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models. Investigational New Drugs 38:5, pages 1272-1281.
Crossref
Crossref
Giulia Culletta, Anna Maria Almerico & Marco Tutone. (2020) Comparing molecular dynamics-derived pharmacophore models with docking: A study on CDK-2 inhibitors. Chemical Data Collections 28, pages 100485.
Crossref
Crossref
Aishani Sachdeva, Jerome Gouge, Christos Kontovounisios, Stella Nikolaou, Alan Ashworth, Kenneth Lim & Irene Chong. (2020) Klotho and the Treatment of Human Malignancies. Cancers 12:6, pages 1665.
Crossref
Crossref
Qing Li, Jiangtao Liu, Yanli Jia, Tingting Li & Mei Zhang. (2020) miR-623 suppresses cell proliferation, migration and invasion through direct inhibition of XRCC5 in breast cancer. Aging 12:11, pages 10246-10258.
Crossref
Crossref
Qunying Jia, Shuhua Chen, Yuan Tan, Yuejin Li & Faqing Tang. (2020) Oncogenic super-enhancer formation in tumorigenesis and its molecular mechanisms. Experimental & Molecular Medicine 52:5, pages 713-723.
Crossref
Crossref
Gatha Thacker, Mukul Mishra, Akshay Sharma, Anil Kumar Singh, Sabyasachi Sanyal & Arun Kumar Trivedi. (2019) CDK2 destabilizes tumor suppressor C/EBPα expression through ubiquitin‐mediated proteasome degradation in acute myeloid leukemia. Journal of Cellular Biochemistry 121:4, pages 2839-2850.
Crossref
Crossref
Ahmed M. Naglah, Ahmed A. Askar, Ashraf S. Hassan, Tamer K. Khatab, Mohamed A. Al-Omar & Mashooq A. Bhat. (2020) Biological Evaluation and Molecular Docking with In Silico Physicochemical, Pharmacokinetic and Toxicity Prediction of Pyrazolo[1,5-a]pyrimidines. Molecules 25:6, pages 1431.
Crossref
Crossref
Koh Fujinaga. (2020) P-TEFb as A Promising Therapeutic Target. Molecules 25:4, pages 838.
Crossref
Crossref
Raoul Tibes & James M. Bogenberger. (2019) Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia. Frontiers in Oncology 9.
Crossref
Crossref
Andrea Ghelli Luserna di Rorà, Giovanni Martinelli & Giorgia Simonetti. (2019) The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?. Journal of Hematology & Oncology 12:1.
Crossref
Crossref
Jianliang Xu, Fei Huang, Zhicheng Yao, Changchang Jia, Zhiyong Xiong, Hao Liang, Nan Lin & Meihai Deng. (2019) Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression. Cell Communication and Signaling 17:1.
Crossref
Crossref
Linh Huynh, Christopher Hipolito & Peter ten Dijke. (2019) A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment. Biomolecules 9:11, pages 743.
Crossref
Crossref
Muhammed H. Rahaman, Frankie Lam, Longjin Zhong, Theodosia Teo, Julian Adams, Mingfeng Yu, Robert W. Milne, Chris Pepper, Noor A. Lokman, Carmela Ricciardelli, Martin K. Oehler & Shudong Wang. (2019) Targeting CDK9 for treatment of colorectal cancer. Molecular Oncology 13:10, pages 2178-2193.
Crossref
Crossref
Huaxin Liang, Zhuo Chen & Libo Sun. (2019) Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl‐1 degradation. Molecular Carcinogenesis 58:8, pages 1502-1511.
Crossref
Crossref
Miller, Park, Saxe, Lew & Raikar. (2019) Clonal Evolution of B-Cell Acute Lymphoblastic Leukemia with del(9)(p13p21) into Mixed Phenotype Acute Leukemia Presenting as an Isolated Testicular Relapse. Reports 2:3, pages 18.
Crossref
Crossref
P. V Bhagwanrao, P. G. Ingole & S. R Butle. (2019) SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-PHENYLPYRIDO[2,3-D] PYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS. INDIAN DRUGS 56:05, pages 50-58.
Crossref
Crossref
Xin Yan, Xiao-Ping Liu, Zi-Xin Guo, Tong-Zu Liu & Sheng Li. (2019) Identification of Hub Genes Associated With Progression and Prognosis in Patients With Bladder Cancer. Frontiers in Genetics 10.
Crossref
Crossref
Domen Ribnikar, Simona Ruxandra Volovat & Fatima Cardoso. (2019) Targeting CDK4/6 pathways and beyond in breast cancer. The Breast 43, pages 8-17.
Crossref
Crossref
Huijuan Nie, Xiaoyan Zhou, Du Shuzhang, Chunjie Nie, Xiaojian Zhang & Jianmin Huang. (2019) Palbociclib overcomes afatinib resistance in non-small cell lung cancer. Biomedicine & Pharmacotherapy 109, pages 1750-1757.
Crossref
Crossref
Pranav Gupta, Silpa Narayanan & Dong-Hua Yang. 2019. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
125
149
.
Amos Burke, Joerg Krueger & Birte Wistinghausen. 2019. Non-Hodgkin's Lymphoma in Childhood and Adolescence. Non-Hodgkin's Lymphoma in Childhood and Adolescence
315
335
.
Dauren Alimbetov, Sholpan Askarova, Bauyrzhan Umbayev, Terence Davis & David Kipling. (2018) Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells. International Journal of Molecular Sciences 19:6, pages 1690.
Crossref
Crossref
Daniel R. Premkumar, Esther P. Jane, Swetha Thambireddy, Philip A. Sutera, Jonathon M. Cavaleri & Ian F. Pollack. (2018) Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl-xL silenced cells. Molecular Carcinogenesis 57:4, pages 469-482.
Crossref
Crossref
Hanxiao Xu, Shengnan Yu, Qian Liu, Xun Yuan, Sridhar Mani, Richard G. Pestell & Kongming Wu. (2017) Recent advances of highly selective CDK4/6 inhibitors in breast cancer. Journal of Hematology & Oncology 10:1.
Crossref
Crossref
Marco Tutone & Anna Maria Almerico. (2017) Recent advances on CDK inhibitors: An insight by means of in silico methods. European Journal of Medicinal Chemistry 142, pages 300-315.
Crossref
Crossref
Honghai Hong, Yingmin Zeng, Wenxuan Jian, Lei Li, Liying Lin, Yousheng Mo, Meiling Liu, Shuhuan Fang & Yong Xia. (2017)
CDK7 inhibition suppresses rheumatoid arthritis inflammation
via
blockage of NF-κB activation and IL-1β/IL-6 secretion
. Journal of Cellular and Molecular Medicine.
Crossref
Crossref
Dorota Lubanska & Lisa Porter. (2017) Revisiting CDK Inhibitors for Treatment of Glioblastoma Multiforme. Drugs in R&D 17:2, pages 255-263.
Crossref
Crossref
Denis O. Okumu, Michael P. East, Merlin Levine, Laura E. Herring, Raymond Zhang, Thomas S. K. Gilbert, David W. Litchfield, Yanping Zhang & Lee M. Graves. (2017) BIRC6 mediates imatinib resistance independently of Mcl-1. PLOS ONE 12:5, pages e0177871.
Crossref
Crossref
Elisabeth Höring, Arnau Montraveta, Simon Heine, Markus Kleih, Lea Schaaf, Matthias C. Vöhringer, Anna Esteve-Arenys, Gael Roué, Dolors Colomer, Elias Campo, German Ott, Walter E. Aulitzky & Heiko van der Kuip. (2017) Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma. British Journal of Haematology 177:4, pages 557-561.
Crossref
Crossref
Steven R. Whittaker, Aurélie Mallinger, Paul Workman & Paul A. Clarke. (2017) Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacology & Therapeutics 173, pages 83-105.
Crossref
Crossref
Koji Ono, Hiroshi Banno, Masanori Okaniwa, Takaharu Hirayama, Naoki Iwamura, Yukiko Hikichi, Saomi Murai, Maki Hasegawa, Yuka Hasegawa, Kazuko Yonemori, Akito Hata, Kazunobu Aoyama & Douglas R. Cary. (2017) Design and synthesis of selective CDK8/19 dual inhibitors: Discovery of 4,5-dihydrothieno[3′,4′:3,4]benzo[1,2- d ]isothiazole derivatives. Bioorganic & Medicinal Chemistry 25:8, pages 2336-2350.
Crossref
Crossref
Christopher R. CoxonElizabeth AnscombeSuzannah J. Harnor, Mathew P. MartinBenoit CarbainBernard T. GoldingIan R. HardcastleLisa K. HarlowSvitlana KorolchukChristopher J. MathesonDavid R. NewellMartin E. M. NobleMangaleswaran SivaprakasamSusan J. TudhopeDavid M. TurnerLan Z. WangStephen R. WedgeChristopher WongRoger J. GriffinJane A. EndicottCéline Cano. (2017) Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. Journal of Medicinal Chemistry 60:5, pages 1746-1767.
Crossref
Crossref
Prithviraj Bose, Pankit Vachhani & Jorge E. Cortes. (2017) Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Current Treatment Options in Oncology 18:3.
Crossref
Crossref
Prithviraj Bose & Varsha Gandhi. (2017) Recent therapeutic advances in chronic lymphocytic leukemia. F1000Research 6, pages 1924.
Crossref
Crossref
Tilahun Ayane Debele, Kuan-Yi Lee, Ning-Yu Hsu, Yi-Ting Chiang, Lu-Yi Yu, Yao-An Shen & Chun-Liang Lo. (2017) A pH sensitive polymeric micelle for co-delivery of doxorubicin and α-TOS for colon cancer therapy. Journal of Materials Chemistry B 5:29, pages 5870-5880.
Crossref
Crossref
Zijie Cai & Qiang Liu. 2017. Translational Research in Breast Cancer. Translational Research in Breast Cancer
251
270
.
Yixiang Chen, Sandra Germano, Chris Clements, Jesvin Samuel, Ghalia Shelmani, Sandrine Jayne, Martin J. S. Dyer & Salvador Macip. (2016) Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia. British Journal of Haematology 175:4, pages 641-651.
Crossref
Crossref
Elizabeth G. GrubbsMichelle D. WilliamsPaul ScheetSelina VattathilNancy D. PerrierJeffrey E. LeeRobert F. GagelTao HaiLei FengMaria E. CabanillasGilbert J. Cote. (2016)
Role of
CDKN2C
Copy Number in Sporadic Medullary Thyroid Carcinoma
. Thyroid 26:11, pages 1553-1562.
Crossref
Crossref
Shao Xie, Hui Jiang, Xiao-wen Zhai, Fan Wei, Shu-dong Wang, Jian Ding & Yi Chen. (2016) Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells. Acta Pharmacologica Sinica 37:11, pages 1481-1489.
Crossref
Crossref
Yogesh A. Sonawane, Margaret A. Taylor, John Victor Napoleon, Sandeep Rana, Jacob I. Contreras & Amarnath Natarajan. (2016) Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. Journal of Medicinal Chemistry 59:19, pages 8667-8684.
Crossref
Crossref
Ajeena Ramanujan & Swati Tiwari. (2016) APC/C and retinoblastoma interaction: cross-talk of retinoblastoma protein with the ubiquitin proteasome pathway. Bioscience Reports 36:5.
Crossref
Crossref
J Johnson, B Thijssen, U McDermott, M Garnett, L F A Wessels & R Bernards. (2016) Targeting the RB-E2F pathway in breast cancer. Oncogene 35:37, pages 4829-4835.
Crossref
Crossref
Hongbin Liu, Phillip Pattie, Sahan Chandrasekara, Andrew Spencer & Anthony E. Dear. (2016) Epigenetic regulation of miRNA-124 and multiple downstream targets is associated with treatment response in myeloid malignancies. Oncology Letters 12:3, pages 2175-2180.
Crossref
Crossref
Emiliano Cocco, Salvatore Lopez, Jonathan Black, Stefania Bellone, Elena Bonazzoli, Federica Predolini, Francesca Ferrari, Carlton L Schwab, Gulden Menderes, Luca Zammataro, Natalia Buza, Pei Hui, Serena Wong, Siming Zhao, Yalai Bai, David L Rimm, Elena Ratner, Babak Litkouhi, Dan-Arin Silasi, Masoud Azodi, Peter E Schwartz & Alessandro D Santin. (2016) Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. British Journal of Cancer 115:3, pages 303-311.
Crossref
Crossref
Chiun Hsu, Liang-In Lin, Yu-Che Cheng, Zi-Rui Feng, Yu-Yun Shao, Ann-Lii Cheng & Da-Liang Ou. (2016) Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression. Clinical Cancer Research 22:10, pages 2555-2564.
Crossref
Crossref
Gian Marco Leggio, Maria Vincenza Catania, Daniela Puzzo, Michela Spatuzza, Rosalia Pellitteri, Walter Gulisano, Sebastiano Alfio Torrisi, Giovanni Giurdanella, Cateno Piazza, Agata Rita Impellizzeri, Lucia Gozzo, Andrea Navarria, Claudio Bucolo, Ferdinando Nicoletti, Agostino Palmeri, Salvatore Salomone, Agata Copani, Filippo Caraci & Filippo Drago. (2016) The antineoplastic drug flavopiridol reverses memory impairment induced by Amyloid-ß 1-42 oligomers in mice. Pharmacological Research 106, pages 10-20.
Crossref
Crossref
Adele Baker, Gareth P. Gregory, Inge Verbrugge, Lev Kats, Joshua J. Hilton, Eva Vidacs, Erwin M. Lee, Richard B. Lock, Johannes Zuber, Jake Shortt & Ricky W. Johnstone. (2016) The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia. Cancer Research 76:5, pages 1158-1169.
Crossref
Crossref
Archana Balakrishnan, Arpita Vyas, Kaivalya Deshpande & Dinesh Vyas. (2016) Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer. World Journal of Gastroenterology 22:7, pages 2159-2164.
Crossref
Crossref
Duong Nhu, Guillaume Lessene, David C. S. Huang & Christopher J. Burns. (2016) Small molecules targeting Mcl-1: the search for a silver bullet in cancer therapy. MedChemComm 7:5, pages 778-787.
Crossref
Crossref
Xiaotian Kong, Huiyong Sun, Peichen Pan, Sheng Tian, Dan Li, Youyong Li & Tingjun Hou. (2016) Molecular principle of the cyclin-dependent kinase selectivity of 4-(thiazol-5-yl)-2-(phenylamino) pyrimidine-5-carbonitrile derivatives revealed by molecular modeling studies. Physical Chemistry Chemical Physics 18:3, pages 2034-2046.
Crossref
Crossref
Martina Palomino-Schätzlein & Antonio Pineda-Lucena. 2016. Cyclin-Dependent Kinase (CDK) Inhibitors. Cyclin-Dependent Kinase (CDK) Inhibitors
211
223
.
Marco Perez, Sandra Muñoz-Galván, Manuel P. Jiménez-García, Juan J. Marín & Amancio Carnero. (2015) Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA. Oncotarget 6:38, pages 40557-40574.
Crossref
Crossref
Loredana Santo, Ka Tat Siu & Noopur Raje. (2015) Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers. Seminars in Oncology 42:6, pages 788-800.
Crossref
Crossref
Paola Indovina, Francesca Pentimalli, Nadia Casini, Immacolata Vocca & Antonio Giordano. (2015) RB1 dual role in proliferation and apoptosis: Cell fate control and implications for cancer therapy. Oncotarget 6:20, pages 17873-17890.
Crossref
Crossref
Martha Schneider, Bianca Tigges, Manja Meggendorfer, Markus Helfer, Christoph Ziegenhain & Ruth Brack-Werner. (2015) A new model for post-integration latency in macroglial cells to study HIV-1 reservoirs of the brain. AIDS 29:10, pages 1147-1159.
Crossref
Crossref
Erica L. Mayer. (2015) Targeting Breast Cancer with CDK Inhibitors. Current Oncology Reports 17:5.
Crossref
Crossref
Prithviraj Bose & Steven Grant. (2015) Rational Combinations of Targeted Agents in AML. Journal of Clinical Medicine 4:4, pages 634-664.
Crossref
Crossref
Yuh-Ying Yeh, Rong Chen, Joshua Hessler, Emilia Mahoney, Amy M. Lehman, Nyla A. Heerema, Michael R. Grever, William Plunkett, John C. Byrd & Amy J. Johnson. (2014) Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia. Oncotarget 6:5, pages 2667-2679.
Crossref
Crossref
Jonathan Reichel, Amy ChadburnPaul G. RubinsteinLisa Giulino-RothWayne TamYifang LiuRafael GaiollaKenneth EngJoshua BrodyGiorgio InghiramiCarmelo Carlo-Stella, Armando SantoroDaoud RahalJennifer TotonchyOlivier Elemento, Ethel Cesarman & Mikhail Roshal. (2015) Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 125:7, pages 1061-1072.
Crossref
Crossref
Amel Hamdi, Aurélien Lesnard, Peggy Suzanne, Thomas Robert, Maria A. Miteva, Morgan Pellerano, Bruno Didier, Elizabeth Ficko-Blean, Annelise Lobstein, Marcel Hibert, Sylvain Rault, May C. Morris & Pierre Colas. (2015) Tampering with Cell Division by Using Small-Molecule Inhibitors of CDK-CKS Protein Interactions. ChemBioChem 16:3, pages 432-439.
Crossref
Crossref
Uzma Asghar, Agnieszka K. Witkiewicz, Nicholas C. Turner & Erik S. Knudsen. (2015) The history and future of targeting cyclin-dependent kinases in cancer therapy. Nature Reviews Drug Discovery 14:2, pages 130-146.
Crossref
Crossref
Jean-François Rossi. (2015) Targeted Therapies in Adult B-Cell Malignancies. BioMed Research International 2015, pages 1-16.
Crossref
Crossref
Carmen Avendaño & J. Carlos Menéndez. 2015. Medicinal Chemistry of Anticancer Drugs. Medicinal Chemistry of Anticancer Drugs
391
491
.
Christopher J Ott. (2014) Promising new strategies to target gene regulatory factors in T-cell acute lymphoblastic leukemia. International Journal of Hematologic Oncology 3:6, pages 379-381.
Crossref
Crossref
Claire Fabre, Marco Gobbi, Cyrine Ezzili, Mustapha Zoubir, Marie-Paule Sablin, Karen Small, Ellie Im, Nabeegha Shinwari, Da Zhang, Honghong Zhou & Christophe Le Tourneau. (2014) Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. Cancer Chemotherapy and Pharmacology 74:5, pages 1057-1064.
Crossref
Crossref
Robert N. Booher, Harold Hatch, Brian M. Dolinski, Thi Nguyen, Lauren Harmonay, Ali-Samer Al-Assaad, Mark Ayers, Michael Nebozhyn, Andrey Loboda, Heather A. Hirsch, Theresa Zhang, Bin Shi, Carrie E. Merkel, Minilik H. Angagaw, Yaolin Wang, Brian J. Long, Xianlu Q. Lennon, Nathan Miselis, Vincenzo Pucci, James W. Monahan, Junghoon Lee, Anna Georgieva Kondic, Eun Kyung Im, David Mauro, Rebecca Blanchard, Gary Gilliland, Stephen E. Fawell, Leigh Zawel, Alwin G. Schuller & Peter Strack. (2014) MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis. PLoS ONE 9:10, pages e108371.
Crossref
Crossref
Prithviraj Bose & Steven Grant. (2014) Orphan drug designation for pracinostat, volasertib and alvocidib in AML. Leukemia Research 38:8, pages 862-865.
Crossref
Crossref
Mark A. Dickson. (2014) Molecular Pathways: CDK4 Inhibitors for Cancer Therapy. Clinical Cancer Research 20:13, pages 3379-3383.
Crossref
Crossref
Yu-Bin Ji, Na Ling, Xiao-Jun Zhou, Yun-Xiang Mao, Wen-Lan Li & Ning Chen. (2014) Schedule-Dependent Effects of Kappa-Selenocarrageenan in Combination with Epirubicin on Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention 15:8, pages 3651-3657.
Crossref
Crossref
Kathleen Keegan, Cong Li, Zhihong Li, Ji Ma, Mark Ragains, Suzanne Coberly, David Hollenback, John Eksterowicz, Lingming Liang, Margaret Weidner, Justin Huard, Xianghong Wang, Grace Alba, Jessica Orf, Mei-Chu Lo, Sharon Zhao, Rachel Ngo, Ada Chen, Lily Liu, Timothy Carlson, Christophe Quéva, Lawrence R. McGee, Julio Medina, Alexander Kamb, Dineli Wickramasinghe & Kang Dai. (2014) Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia. Molecular Cancer Therapeutics 13:4, pages 880-889.
Crossref
Crossref
Patrizia Bonelli, Franca Maria Tuccillo, Antonella Borrelli, Antonietta Schiattarella & Franco Maria Buonaguro. (2014) CDK/CCN and CDKI Alterations for Cancer Prognosis and Therapeutic Predictivity. BioMed Research International 2014, pages 1-15.
Crossref
Crossref
Mark S. Butler, Avril A. B. Robertson & Matthew A. Cooper. (2014) Natural product and natural product derived drugs in clinical trials. Nat. Prod. Rep. 31:11, pages 1612-1661.
Crossref
Crossref
A. Mortlock, K. Foote, J. Kettle & B. Aquila. 2014. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering.
Céline Bruyère & Laurent Meijer. (2013) Targeting cyclin-dependent kinases in anti-neoplastic therapy. Current Opinion in Cell Biology 25:6, pages 772-779.
Crossref
Crossref